Novel and safe single-dose treatment of cutaneous leishmaniasis with implantable amphotericin B-loaded microparticles

The development of an effective amphotericin B (AmB) topical formulation to replace the systemically toxic injections currently used in cutaneous leishmaniasis (CL) treatment is challenging due to poor absorption through the skin. Aiming at an effective local chemotherapy, we designed PLGA (poly(lac...

Descripción completa

Detalles Bibliográficos
Autores principales: Sousa-Batista, Ariane J., Pacienza-Lima, Wallace, Ré, Maria Inês, Rossi-Bergmann, Bartira
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Includes articles from the special issue “Novel therapies for cutaneous leishmaniasis”, pp. 106 - 179
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6904829/
https://www.ncbi.nlm.nih.gov/pubmed/31331828
http://dx.doi.org/10.1016/j.ijpddr.2019.06.001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6904829/
https://www.ncbi.nlm.nih.gov/pubmed/31331828
http://dx.doi.org/10.1016/j.ijpddr.2019.06.001

Ejemplares similares